Gina Tomaine

News

Zanubrutinib Prolongs PFS vs Bendamustine-Rituximab in Untreated CLL and SLL: SEQUOIA Trial

08/23/2022

Zanubrutinib significantly improved PFS vs bendamustine–rituximab, with an acceptable safety profile, as a frontline therapy for patients with CLL and SLL, according to results from the phase 3 SEQUOIA trial.

Zanubrutinib significantly...

08/23/2022

Oncology

News

Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis

09/30/2022

Gina Tomaine ;

Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.

Both conventional cytoreduction...

09/30/2022

Oncology

News

Mosunetuzumab Induces High Rates of Complete Remission in Relapsed/Refractory Follicular Lymphoma

09/01/2022

Gina Tomaine ;

Fixed-duration mosunetuzumab demonstrates a favorable safety profile and induces high rates of complete remission in patients with relapsed or refractory follicular lymphoma who received ≥2 prior therapies, according to a phase 2 study.

Fixed-duration mosunetuzumab...

09/01/2022

Oncology

News

Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera

07/14/2023

Gina Tomaine ;

A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.

A new dosing regimen of...

07/14/2023

Oncology

News

Posttransplant Cyclophosphamide Plus Cyclosporine A Effectively Prevents Severe GVHD: HOVON-96 Trial

07/18/2022

Gina Tomaine ;

Study findings suggest posttransplant cyclophosphamide effectively prevents severe GVHD and could allow for implementation of early posttransplant chemotherapy and immunotherapy to further reduce risk of relapse after alloHSCT.

Study findings suggest...

07/18/2022

Oncology

Conference Coverage

Tolerability and Efficacy of Azacitidine Plus Venetoclax Maintenance for Patients With AML

12/11/2022

Gina Tomaine ;

Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.

Low-dose azacitidine plus...

12/11/2022

Oncology

News

Mezigdomide and Dexamethasone Combination Demonstrates Promising Efficacy for Patients With R/R Multiple Myeloma

09/29/2023

Gina Tomaine ;

Oral mezigdomide combined with dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory multiple myeloma, according to a phase 1/2 study.

Oral mezigdomide combined with...

09/29/2023

Oncology

News

Second-Line Lisocabtagene Maraleucel vs Standard of Care for Relapsed/Refractory LBCL: TRANSFORM Trial

08/23/2022

Gina Tomaine ;

An interim analysis of the phase 3 TRANSFORM trial has shown significantly improved EFS with second-line lisocabtagene maraleucel vs standard of care salvage immunochemotherapy followed by autologous stem cell transplantation in relapsed or...

An interim analysis of the phase...

08/23/2022

Oncology

News

FDA Grants Expedited Approval to Omidubicel for Patients With Hematologic Malignancies

04/18/2023

Gina Tomaine ;

The FDA granted approval to omidubicel-onlv treatment for patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning.

The FDA granted approval to...

04/18/2023

Oncology

News

Lenalidomide Plus Rituximab vs Rituximab and Chemotherapy for Untreated Follicular Lymphoma

09/01/2022

Gina Tomaine ;

Lenalidomide plus rituximab provides an acceptable alternative to rituximab plus chemotherapy for patients with untreated advanced follicular lymphoma, according to long-term results from the RELEVANCE trial.

Lenalidomide plus rituximab...

09/01/2022

Oncology